Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts

British Journal of Cancer

Volumn 67, Issue 1, 1993, Pages 24-29

  Jones, M ^a   Siracky, J ^b   Kelland, L R ^a   Harrap, K R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; IPROPLATIN; PLATINUM; TETRAPLATIN;

ARTICLE; CROSS RESISTANCE; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMAL; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DRUG RESISTANCE; FEMALE; HUMAN; KARYOTYPING; MICE; MICE, INBRED STRAINS; MODELS, BIOLOGICAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; SUPPORT, NON-U.S. GOV'T; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0027455426     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1993.5     Document Type: Article

References (30)

1. ADVANCED OVARIAN CANCER TRIALISTS GROUP (1991). Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br. Med. J., 303, 884-893
2. ANDREWS, P.A. & HOWELL, S.B. (1990a). Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2, 35-43
3. ANDREWS, P.A., JONES, J.A., VARKI, N.M. & HOWELL, S.B. (1990b). Rapid emergence of acquired cis-Diamminedichloror platinum (II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun., 2, 93-100
4. BEHRENS, B.C., HAMILTON, T.C., MASUDA, H., GROTZINGER, K.R., WHANG-PENG, J., LOUIE, K.G., KNUTSEN, T., MCKOY, W.M., YOUNG, R.C. & OZOLS, R.F. (1987). Characterization of a cis-diamminedichloroplatinum (II)-resistant human ovarian carcinoma cell line and its use in evaluation of platinum analogs. Cancer Res., 47, 414-418
5. BURCHENAL, J.H., KALAHER, K., O’TOOLE, T. & CHISHOLM, J. (1977). Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia. Cancer Res., 37, 2455-2457
6. CHRISTIAN, M.C., SPRIGGS, D., TUTSCH, K.D., O’ROURKE, T., VON HOFF, D., JACOB, J.L. & REED, E. (1991). Phase I trials with Ormaplatin (tetraplatin). In Platinum and Other Metal Coordination Complexes in Cancer Chemotherapy. Howell, S.B. ed. Plenum Press: New York, 453-458
7. EISENHAUER, E., SWERTON, K., STURGEON, J., FINE, S., O’REILLY, S. & CANETTA, R. (1990). Carboplatin therapy for recurrent ovarian carcinoma: National Cancer Institute of Canada experience and a review of the literature. In Bunn, P., Canetra, R., Ozols, R. & Rozencweig, M. eds, Carboplatin: Current Perspectives and Future Directions, pp. 133-140, Philadelphia: W.B. Saunders Company
8. FERRARI, A., DAMIA, G., ERBA, E., MANDELLI, R. & D INCALCI, M. (1989). Characterization of a novel mouse reticular cell sarcoma M5076 subline resistant to cisplatin. Int. J. Cancer, 43, 1091-1097
9. GODDARD, P.M., VALENTI, M R. & HARRAP, K.R. (1991). The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note. Annals Oncol., 2, 535-540
10. GORE, M E., FRYATT, I., WILTSHAW, E., DAWSON, T., ROBINSON, B.A. & CALVERT, A.H. (1989). Cisplatin/carboplatin crossresistance in ovarian cancer. Br. J. Cancer, 60, 767-769
11. HARRAP, K.R., JONES, M., SIRACKY, J., POLLARD, L. & KELLAND, L.R. (1990). The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Annals Oncol., 1, 65-76
12. HILLS, C.A., KELLAND, L.R., ABEL, G., SIRACKY, J., WILSON, A.P. & HARRAP, K.R. (1989). Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer, 59, 527-534
13. HOSPERS, G.A.P., MULDER, N.H., DE JONG, B., DE LEY, L., UGES, D.R.A., FICHTINGER-SCHEPMAN, A.M.J., SCHEPER, R.J. & DE VRIES, E.G.E. (1988). Characterization of a human small cell lung carcinoma cell line with acquired resistance to cw-Diammine-dichloro platinum (II) in vitro. Cancer Res., 48, 6803-6807
14. KELLAND, L.R., MURRER, B.A., ABEL, G., GIANDOMENICO, C M., MISTRY, P. & HARRAP, K.R. (1992a). Ammine/amine platinum (IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian cell lines. Cancer Res., 52, 822-828
15. KELLAND, L.R., JONES, M., ABEL, G. & HARRAP, K.R. (1992b). Human ovarian carcinoma cell lines and companion xenografts: a disease oriented approach to new platinum anticancer drug development. Cancer Chemother. Pharmacol., 30, 43-50
16. KELLAND, L.R., MISTRY, P., ABEL, G., LOH, S.Y., O’NEILL, C.F., MURRER, B.A. & HARRAP, K.R. (1992c). Mechanism-related circumvention of cis-diamminedicholoroplatinum (II) acquired resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum (IV) dicarboxylates. Cancer Res., 52, 3857-3864
17. MANGIONI, C., BOLIS, G., PECORELLI, S., BRAGMAN, K., EPIS, A., FAVALLI, G., GAMBINO, A., LANDONI, F., PRESTI, M., TORRI, W., VASSENA, L., ZANABONI, F. & MARSONI, S. (1989). Randomised trial in ovarian cancer comparing cisplatin and carboplatin. J. Natl Cancer Inst., 81, 1464-1468
18. MCKEAGE, M.J., HIGGINS, J.D. (III). & KELLAND, L.R. (1991). Platinum and other metal coordination compounds in cancer chemotherapy. Br. J. Cancer, 64, 788-792
19. MISTRY, P., KELLAND, L.R., ABEL, G., SIDHAR, S. & HARRAP, K.R. (1991). The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer, 64, 215-220
20. OZOLS, R.F. (1991). Ovarian cancer: new clinical approaches. Cancer Treat. Rev., 18 (suppl A), 77-83
21. ROBERTS, J.J., KNOX, R.J., FRIEDLOS, F. & LYDALL, D A. (1986). DNA as the target for the cytotoxic and anti-tumour action of platinum co-ordination complexes: comparative in vitro and in vivo studies of cisplatin and carboplatin. In McBrien, D.C.H. and Slater, T.F. eds, Biochemical Mechanisms of Platinum Antitumour Drugs, pp. 29-64. Oxford: IRL Press
22. ROSE, W.C. & BASLER, G.A. (1990). In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas. In Vivo, 4, 391-396
23. SCHAPEL, F.M. Jr, SKIPPER, H E., TRADER, M.W., LASTER, W.R. Jr., GRISWOLD, D.P. Jr. & CORBETT, T.H. (1983). Establishment of cross-resistance profiles for new agents. Cancer Treat. Rep., 67, 905-922
24. SEEBER, S., OSIEKA, R., SCHMIDT, C.G., ACHTERRATH, W. & CROOKE, S.T. (1982). In vivo resistance towards anthracyclines, etoposide and cis-diamminedichloro platinum (II). Cancer Res., 42, 4719-4725
25. SESSA, C., VERMORKEN, J., RENARD, J., KAYE, S., SMITH, D., HUININK, TEN BOKKEL, W., CAVALLI, F. & PINEDO, H. (1988). Phase II study of iproplatin in advanced ovarian carcinoma. J. Clin. Oncol., 6, 98-105
26. STEEL, G.G., COURTENAY, V.D. & PECKHAM, M.J. (1983). The response to chemotherapy of a variety of human tumour xenografts. Br. J. Cancer, 47, 1-13
27. TEICHER, B.A., HERMAN, T.S., HOLDEN, S.A., WANG, Y.M., PEEF-FER, R., CRAWFORD, J.W. & FREI, E. III. (1990). Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science, 245, 1457-1461
28. WAUD, W.R., HARRISON, S.D. Jr., GILBERT, K.S., LASTER, W.R. Jr. & GRISWOLD, D.P. Jr. (1991). Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia. Cancer Chemother. Pharmacol., 27, 456-463
29. WEISS, G., GREEN, S., ALBERTS, D.S., THIGPEN, J.T., HINES, H.E., HANSON, K., PIERCE, HI., BAKER, L.H. & GOODWIN, J.W. (1991). Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study. Eur. J. Cancer, 27, 135-138
30. ZELLER, W.J., FRUHAUF, S., CHEN, G., KEPPLER, B.K., FREI, E. & KAUFMANN, M. (1991). Chemoresistance in rat ovarian tumours. Eur. J. Cancer, 27, 62-67